Status:
COMPLETED
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Cervical Cancer
Genital Warts
Eligibility:
FEMALE
16-23 years
Phase:
PHASE3
Brief Summary
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any ...
Eligibility Criteria
Inclusion
- Female with an intact uterus with lifetime history of 0-4 sexual partners
Exclusion
- Prior Human Papillomavirus (HPV) vaccination
- Prior abnormal paps
- History of genital warts
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
5759 Patients enrolled
Trial Details
Trial ID
NCT00092521
Start Date
December 1 2001
End Date
January 1 2009
Last Update
September 25 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.